dexamethasone intravitreal implant


Generic Name:
dexamethasone intravitreal implant
Project Status:
Therapeutic Area:
Diabetic macular edema
Allergan, an AbbVie Company
Brand Name:
Project Line:
Reimbursement Review
Project Number:
NOC Status at Filing:
Post NOC
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with DME who are pseudophakic and have had an inadequate response to prior anti-vascular endothelial growth factors (VEGF) therapy.
Submission Type:
Fee Schedule:
Schedule A
For the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic.
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openMay 09, 2022
Call for patient/clinician input closedJuly 04, 2022

- Patient input submission received from CNIB, Diabetes Canada, Fighting Blindness Canada, The Canadian Council of the Blind and Vision Loss Rehabilitation Canada

Submission receivedJune 08, 2022
Submission acceptedJune 22, 2022
Review initiatedJune 23, 2022
Draft CADTH review report(s) provided to sponsor for commentSeptember 12, 2022
Deadline for sponsors commentsSeptember 21, 2022
CADTH review report(s) and responses to comments provided to sponsorOctober 14, 2022
Expert committee meeting (initial)October 26, 2022
Draft recommendation issued to sponsorNovember 09, 2022
Draft recommendation posted for stakeholder feedbackNovember 17, 2022
End of feedback periodDecember 01, 2022
Final recommendation issued to sponsor and drug plansDecember 13, 2022
Final recommendation postedJanuary 06, 2023
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)January 04, 2023
CADTH review report(s) postedMarch 10, 2023